323 related articles for article (PubMed ID: 24855036)
1. A pharmacogenetic survey of androgen receptor (CAG)n and (GGN)n polymorphisms in patients experiencing long term side effects after finasteride discontinuation.
Cecchin E; De Mattia E; Mazzon G; Cauci S; Trombetta C; Toffoli G
Int J Biol Markers; 2014 Dec; 29(4):e310-6. PubMed ID: 24855036
[TBL] [Abstract][Full Text] [Related]
2. Androgen Receptor (AR) Gene (CAG)n and (GGN)n Length Polymorphisms and Symptoms in Young Males With Long-Lasting Adverse Effects After Finasteride Use Against Androgenic Alopecia.
Cauci S; Chiriacò G; Cecchin E; Toffoli G; Xodo S; Stinco G; Trombetta C
Sex Med; 2017 Mar; 5(1):e61-e71. PubMed ID: 28024997
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical evaluation of androgen receptor and nerve structure density in human prepuce from patients with persistent sexual side effects after finasteride use for androgenetic alopecia.
Di Loreto C; La Marra F; Mazzon G; Belgrano E; Trombetta C; Cauci S
PLoS One; 2014; 9(6):e100237. PubMed ID: 24959691
[TBL] [Abstract][Full Text] [Related]
4. An observational retrospective evaluation of 79 young men with long-term adverse effects after use of finasteride against androgenetic alopecia.
Chiriacò G; Cauci S; Mazzon G; Trombetta C
Andrology; 2016 Mar; 4(2):245-50. PubMed ID: 26763726
[TBL] [Abstract][Full Text] [Related]
5. Androgenetic alopecia; drug safety and therapeutic strategies.
Motofei IG; Rowland DL; Baconi DL; Tampa M; Sârbu MI; Păunică S; Constantin VD; Bălălău C; Păunică I; Georgescu SR
Expert Opin Drug Saf; 2018 Apr; 17(4):407-412. PubMed ID: 29363345
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic hotline. Genetic variations in the androgen receptor gene and finasteride response in women with androgenetic alopecia mediated by epigenetics.
Keene S; Goren A
Dermatol Ther; 2011; 24(2):296-300. PubMed ID: 21410621
[TBL] [Abstract][Full Text] [Related]
7. Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis.
Belknap SM; Aslam I; Kiguradze T; Temps WH; Yarnold PR; Cashy J; Brannigan RE; Micali G; Nardone B; West DP
JAMA Dermatol; 2015 Jun; 151(6):600-6. PubMed ID: 25830296
[TBL] [Abstract][Full Text] [Related]
8. Research Brief: Self-Reports of a Constellation of Persistent Antiandrogenic, Estrogenic, Physical, and Psychological Effects of Finasteride Usage Among Men.
Walf AA; Kaurejo S; Frye CA
Am J Mens Health; 2018 Jul; 12(4):900-906. PubMed ID: 29318957
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of efficacy and safety of finasteride 1 mg in 3177 Japanese men with androgenetic alopecia.
Sato A; Takeda A
J Dermatol; 2012 Jan; 39(1):27-32. PubMed ID: 21980923
[TBL] [Abstract][Full Text] [Related]
10. Adverse Effects of 5-Alpha Reductase Inhibitor Therapy in Men With Androgenetic Alopecia: Is There Cause for Concern?
Arias-Santiago S; Camacho-Martínez FM
Actas Dermosifiliogr; 2016 Nov; 107(9):709-711. PubMed ID: 27436801
[No Abstract] [Full Text] [Related]
11. Dutasteride in Androgenetic Alopecia: An Update.
Arif T; Dorjay K; Adil M; Sami M
Curr Clin Pharmacol; 2017; 12(1):31-35. PubMed ID: 28294070
[TBL] [Abstract][Full Text] [Related]
12. [Finasteride adverse effects: An update].
Carreño-Orellana N; Moll-Manzur C; Carrasco-Zuber JE; Álvarez-Véliz S; Berroeta-Mauriziano D; Porras-Kusmanic N
Rev Med Chil; 2016 Dec; 144(12):1584-1590. PubMed ID: 28393993
[TBL] [Abstract][Full Text] [Related]
13. Post-finasteride syndrome - does it really exist?
Maksym RB; Kajdy A; Rabijewski M
Aging Male; 2019 Dec; 22(4):250-259. PubMed ID: 30651009
[TBL] [Abstract][Full Text] [Related]
14. Finasteride and androgenic alopecia; from therapeutic options to medical implications.
Motofei IG; Rowland DL; Tampa M; Sarbu MI; Mitran MI; Mitran CI; Stoian AP; Diaconu CC; Paunica S; Georgescu SR
J Dermatolog Treat; 2020 Jun; 31(4):415-421. PubMed ID: 30897009
[TBL] [Abstract][Full Text] [Related]
15. Finasteride, 1 mg daily administration on male androgenetic alopecia in different age groups: 10-year follow-up.
Rossi A; Cantisani C; Scarnò M; Trucchia A; Fortuna MC; Calvieri S
Dermatol Ther; 2011; 24(4):455-61. PubMed ID: 21910805
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic hotline. Treatment of androgenic alopecia with finasteride may result in a high grade prostate cancer in patients: fact or fiction?
Lynn R; Krunic A
Dermatol Ther; 2010; 23(5):544-6. PubMed ID: 20868409
[TBL] [Abstract][Full Text] [Related]
17. Blockade of Androgen Markers Using a Novel Betasitosterol, Thioctic Acid and Carnitine-containing Compound in Prostate and Hair Follicle Cell-based Assays.
Chen L; Wang J; Mouser G; Li YC; Marcovici G
Phytother Res; 2016 Jun; 30(6):1016-20. PubMed ID: 26990224
[TBL] [Abstract][Full Text] [Related]
18. Atypical post-finasteride syndrome: A pharmacological riddle.
Gupta AK; Sharma N; Shukla P
Indian J Pharmacol; 2016; 48(3):316-7. PubMed ID: 27298504
[TBL] [Abstract][Full Text] [Related]
19. Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?
Traish AM; Melcangi RC; Bortolato M; Garcia-Segura LM; Zitzmann M
Rev Endocr Metab Disord; 2015 Sep; 16(3):177-98. PubMed ID: 26296373
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic experience with oral finasteride for androgenetic alopecia in female-to-male transgender patients.
Moreno-Arrones OM; Becerra A; Vano-Galvan S
Clin Exp Dermatol; 2017 Oct; 42(7):743-748. PubMed ID: 28691187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
